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BACKGROUND
Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. 
The long-term efficacy and safety of edoxaban as compared with warfarin in patients 
with atrial fibrillation is not known.
METHODS
We conducted a randomized, double-blind, double-dummy trial comparing two 
once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-
to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy 
end point was stroke or systemic embolism. Each edoxaban regimen was tested for 
noninferiority to warfarin during the treatment period. The principal safety end 
point was major bleeding.
RESULTS
The annualized rate of the primary end point during treatment was 1.50% with 
warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% 
with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 
to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 
1.07; 97.5% CI, 0.87 to 1.31; P = 0.005 for noninferiority). In the intention-to-treat 
analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard 
ratio, 0.87; 97.5% CI, 0.73 to 1.04; P = 0.08) and an unfavorable trend with low-dose 
edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P = 0.10). The 
annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-
dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with 
low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corre-
sponding annualized rates of death from cardiovascular causes were 3.17% versus 
2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P = 0.01), and 2.71% (hazard ratio, 
0.85; 95% CI, 0.76 to 0.96; P = 0.008), and the corresponding rates of the key second-
ary end point (a composite of stroke, systemic embolism, or death from cardiovas-
cular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; 
P = 0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P = 0.32).
CONCLUSIONS
Both once-daily regimens of edoxaban were noninferior to warfarin with respect to 
the prevention of stroke or systemic embolism and were associated with significantly 
lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi 
Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, 
NCT00781391.)
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Edoxaban is an oral, reversible, di-rect factor Xa inhibitor with a linear and predictable pharmacokinetic profile and 
62% oral bioavailability.1 It achieves maximum 
concentrations within 1 to 2 hours, and 50% is 
excreted by the kidney.2 A randomized, dose-
ranging, warfarin-controlled, phase 2 study in-
volving 1146 patients with atrial fibrillation 
showed that once-daily doses of edoxaban (60 mg 
or 30 mg) were safer than twice-daily doses.3 
Pharmacokinetic modeling and simulation showed 
that patients with low body weight, moderate-to-
severe renal dysfunction, or concomitant use of a 
potent P-glycoprotein inhibitor should have the 
edoxaban dose reduced by 50%.4 A phase 3 study 
involving 8292 patients with acute venous throm-
boembolism showed that once-daily edoxaban at 
a dose of 60 mg (reduced to 30 mg in selected 
patients) was as effective as warfarin for the pre-
vention of recurrent symptomatic venous throm-
boembolism and was associated with a signifi-
cantly lower rate of bleeding.5 We compared two 
dose regimens of once-daily edoxaban with war-
farin in patients with atrial fibrillation who were 
at moderate-to-high risk for stroke.
ME THODS
STUDY OVERSIGHT
The trial was designed and led by an executive 
committee, in coordination with an international 
steering committee (see the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org). The protocol and amendments were 
approved by the ethics committee at each par-
ticipating center. All the patients provided writ-
ten informed consent. An independent data and 
safety monitoring committee performed multiple 
safety reviews. The Thrombolysis in Myocardial 
Infarction Study Group coordinated the trial and 
performed all the analyses independently using 
raw data. Quintiles, a contract research organi-
zation, managed the database and monitored the 
study sites. All the authors participated in the 
design of the trial and in the analysis of the data. 
The first author wrote the first draft of the manu-
script, and all the authors participated in subse-
quent drafts and made the decision to submit the 
manuscript for publication. All the authors vouch 
for the accuracy and completeness of the data 
and the fidelity of the study to the protocol, 
which is available at NEJM.org. There were no con-
tractual agreements with the sponsor that could 
have denied the investigators the right to examine 
the data independently or submit the manuscript 
for publication without consent of the sponsor.
TRIAL DESIGN
The Effective Anticoagulation with Factor Xa Next 
Generation in Atrial Fibrillation–Thrombolysis in 
Myocardial Infarction 48 (ENGAGE AF-TIMI 48) 
trial was a three-group, randomized, double-
blind, double-dummy trial comparing two dose 
regimens of edoxaban with warfarin. We con-
ducted the trial at 1393 centers in 46 countries 
(see the Supplementary Appendix). Patients were 
enrolled during the period from November 19, 
2008, through November 22, 2010. The protocol 
and statistical analysis plan have been described 
previously.6
STUDY POPULATION
Eligible patients were 21 years of age or older and 
had atrial fibrillation documented by means of 
an electrical tracing within the 12 months pre-
ceding randomization, a score of 2 or higher on 
the CHADS2 risk assessment, and anticoagulation 
therapy planned for the duration of the trial.7 
Scores on the CHADS2 range from 0 to 6, with 
higher scores indicating a greater risk of stroke; 
congestive heart failure, hypertension, diabetes, 
and an age of 75 years or older are each assigned 
1 point, and prior stroke or transient ischemic 
attack is assigned 2 points. Key exclusion criteria 
were atrial fibrillation due to a reversible disor-
der; an estimated creatinine clearance of less 
than 30 ml per minute; a high risk of bleeding; 
use of dual antiplatelet therapy; moderate-to-
severe mitral stenosis; other indications for anti-
coagulation therapy; acute coronary syndromes, 
coronary revascularization, or stroke within 30 
days before randomization; and an inability to 
adhere to study procedures.6
RANDOMIZATION AND STUDY DRUGS
Patients were randomly assigned, in a 1:1:1 ratio, 
to receive warfarin, dose-adjusted to achieve an 
international normalized ratio (INR) of 2.0 to 3.0, 
or to receive high-dose or low-dose edoxaban. 
Randomization was performed with the use of a 
central, 24-hour, interactive, computerized re-
sponse system. Patients who were already taking 
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a vitamin K antagonist underwent randomiza-
tion after the INR was 2.5 or less. Randomization 
was stratified according to the following charac-
teristics: CHADS2 score of 2 or 3 versus a score of 
4, 5, or 6 and status with respect to the need for 
a reduction in the edoxaban dose.6
The high-dose edoxaban group received 60 mg, 
and the low-dose group 30 mg. For patients in 
either group, the dose was halved if any of the 
following characteristics were present at the time 
of randomization or during the study: estimated 
creatinine clearance of 30 to 50 ml per minute, 
a body weight of 60 kg or less, or the con-
comitant use of verapamil or quinidine (potent 
P-glycoprotein inhibitors). A protocol amendment 
on December 22, 2010, mandated similar dose 
modifications in the case of concomitant use of 
dronedarone. After randomization, standard dos-
ing was resumed if verapamil, quinidine, or 
dronedarone was discontinued and if there had 
been no other reason for a reduction of the 
edoxaban dose. Each patient received two sets of 
study drugs: either active edoxaban and a pla-
cebo matching warfarin, or a placebo matching 
edoxaban and active warfarin.
The INR was measured at least monthly with 
the use of an encrypted point-of-care device. To 
maintain blinding, sham INR values were gener-
ated for patients who were randomly assigned to 
edoxaban. The time in the therapeutic range in 
the warfarin group was calculated by means of 
linear interpolation,8 with INR values rounded 
to the nearest 0.1.9 Study visits were scheduled on 
days 8, 15, 29, and 60, at month 3, and at least 
every 3 months thereafter.
At the end of the trial, patients made the 
transition to open-label oral anticoagulation ther-
apy with the use of a detailed plan (see the study 
protocol). Patients who made the transition from 
edoxaban to an open-label vitamin K antagonist 
received both active low-dose edoxaban and an 
open-label vitamin K antagonist until the INR 
reached 2.0 or for 2 weeks (whichever came first). 
At least three INR measurements were mandated 
between days 4 and 14 of the transition period; 
the use of an approved dosing algorithm for the 
vitamin K antagonist was required.
STUDY END POINTS
The primary efficacy end point was the time to 
the first adjudicated stroke (ischemic or hemor-
rhagic) or systemic embolic event. The principal 
safety end point was adjudicated major bleeding 
during treatment, as defined by the International 
Society on Thrombosis and Haemostasis.10 Key 
secondary composite end points included the fol-
lowing: stroke, systemic embolic event, or death 
from cardiovascular causes (including bleeding); 
myocardial infarction, stroke, systemic embolic 
event, or death from cardiovascular causes; and 
stroke, systemic embolic event, or death from 
any cause. Net clinical end points included com-
posites of stroke, systemic embolic event, major 
bleeding, or death; disabling stroke, life-threat-
ening bleeding, or death; and stroke, systemic 
embolic event, life-threatening bleeding, or 
death.
An independent clinical end-point committee, 
whose members were unaware of the study as-
signment, adjudicated all deaths and suspected 
cerebrovascular events, systemic embolic events, 
myocardial infarctions, bleeding events, and he-
patic events. Details of the definitions used by 
the clinical end-point committee are provided in 
the protocol.
STATISTICAL ANALYSIS
The primary efficacy analysis, which tested 
whether either dose regimen of edoxaban was 
noninferior to warfarin, was performed with the 
use of a Cox proportional-hazards model that in-
cluded treatment groups and the two randomiza-
tion stratification factors. This analysis included 
data from patients who underwent randomiza-
tion and received at least one dose of the study 
drug during the treatment period (modified 
 intention-to-treat population). The treatment pe-
riod was defined as the period between adminis-
tration of the first dose of the study drug and 
either 3 days after the receipt of the last dose or 
the end of the double-blind therapy (whichever 
came first), with interval censoring of events 
during study-drug interruptions that lasted more 
than 3 days. To satisfy noninferiority, the upper 
boundary of the one-sided 97.5% confidence in-
terval for the hazard ratio of the primary efficacy 
end point comparing edoxaban with warfarin 
could not exceed 1.38, which was an estimate 
that preserved at least 50% of the benefit of war-
farin over placebo.11,12
If an edoxaban dosing regimen met the pre-
specified criteria for noninferiority, that dose 
The New England Journal of Medicine 
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was then compared with warfarin in a test of 
superiority with the use of data from the inten-
tion-to-treat population, with all primary-end-
point events that occurred during the overall 
study period (i.e., from randomization to the 
end of the treatment period) considered in the 
analysis. To control the overall rate of a type I 
error with a two-sided alpha significance level of 
Table 1. Demographic and Clinical Characteristics of the Patients.*
Characteristic
Warfarin
(N = 7036)
High-Dose 
Edoxaban 
(N = 7035)
Low-Dose 
Edoxaban 
(N = 7034)
Age — yr
Median 72 72 72
Interquartile range 64–78 64–78 64–78
Female sex — no. (%) 2641 (37.5) 2669 (37.9) 2730 (38.8)
Region — no. (%)
North America 1562 (22.2) 1559 (22.2) 1560 (22.2)
Latin America 888 (12.6) 886 (12.6) 887 (12.6)
Western Europe 1078 (15.3) 1079 (15.3) 1079 (15.3)
Eastern Europe 2381 (33.8) 2383 (33.9) 2380 (33.8)
Asia–Pacific region and South Africa 1127 (16.0) 1128 (16.0) 1128 (16.0)
Paroxysmal atrial fibrillation — no. (%) 1778 (25.3) 1753 (24.9) 1835 (26.1)
Qualifying risk factor — no. (%)
Age ≥75 yr 2820 (40.1) 2848 (40.5) 2806 (39.9)
Prior stroke or transient ischemic attack 1991 (28.3) 1976 (28.1) 2006 (28.5)
Congestive heart failure 4048 (57.5) 4097 (58.2) 3979 (56.6)
Diabetes mellitus 2521 (35.8) 2559 (36.4) 2544 (36.2)
Hypertension requiring treatment 6588 (93.6) 6591 (93.7) 6575 (93.5)
CHADS2 score† 2.8±1.0 2.8±1.0 2.8±1.0
≤3 — no. (%) 5445 (77.4) 5422 (77.1) 5470 (77.8)
4–6 — no. (%) 1591 (22.6) 1613 (22.9) 1564 (22.2)
Dose reduction at randomization — no. (%)‡ 1787 (25.4) 1784 (25.4) 1785 (25.4)
Creatinine clearance ≤50 ml/min 1361 (19.3) 1379 (19.6) 1334 (19.0)
Weight ≤60 kg 701 (10.0) 684 (9.7) 698 (9.9)
Use of verapamil or quinidine 243 (3.5) 258 (3.7) 260 (3.7)
Previous use of vitamin K antagonist for ≥60 days — no. (%) 4138 (58.8) 4140 (58.8) 4163 (59.2)
Medication at time of randomization — no. (%)
Aspirin 2092 (29.7) 2070 (29.4) 2018 (28.7)
Thienopyridine 164 (2.3) 174 (2.5) 149 (2.1)
Amiodarone 827 (11.8) 866 (12.3) 799 (11.4)
Digoxin or digitalis preparation 2176 (30.9) 2078 (29.5) 2073 (29.5)
* Plus–minus values are means ±SD. There were no significant differences between the treatment groups in any of the characteristics listed.
† Scores on the CHADS2 range from 0 to 6, with higher scores indicating a greater risk of stroke; congestive heart failure, hypertension,  
diabetes, and an age of 75 years or older are each assigned 1 point, and prior stroke or transient ischemic attack is assigned 2 points.
‡ Patients with a creatinine clearance of 50 ml per minute or less, those with a body weight of 60 kg or less, and those who were receiving the 
concomitant potent P-glycoprotein inhibitors verapamil or quinidine at randomization received a dose of edoxaban that was reduced by 
50% to maintain an exposure level similar to that of patients who did not have any of these three factors. Patients may have had more than 
one reason for dose adjustment.
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0.025 for superiority, sequential multiplicity-
adjustment procedures (closed testing) were used 
in a hierarchical fashion to test secondary end 
points in the intention-to-treat population (Fig. 
S1 in the Supplementary Appendix). We calculat-
ed that with approximately 672 primary-end-point 
events, the study would have more than 87% 
power to reject the null hypothesis that edoxa-
ban was inferior to warfarin.6
R ESULT S
PATIENTS AND FOLLOW-UP
The characteristics of the patients at baseline 
were well balanced (Table 1). Complete informa-
tion on the primary end point was ascertained 
for 99.5% of the total 56,346 patient-years of po-
tential follow-up (Fig. S2 in the Supplementary 
Appendix). One patient was lost to follow-up, and 
244 patients withdrew consent to follow-up; 182 
of these patients had no known primary-end-
point event and were not known to be dead.
STUDY DRUGS
A total of 21,105 patients underwent randomiza-
tion, of whom 21,026 (99.6%) received the study 
drug. A total of 5330 patients (25.3%) received a 
reduced dose of edoxaban or matching placebo at 
randomization, with similar rates in the three 
treatment groups. After randomization, dose re-
ductions occurred in 7.1% of the patients, and 
dose increases in 1.2%, with similar rates in the 
three treatment groups. The median duration of 
treatment exposure was 907 days, excluding in-
terruptions; the median follow-up was 1022 days 
(2.8 years).
Fewer patients in the warfarin group than in 
either edoxaban group completed the study with-
out drug interruption (2421 in the warfarin 
group, as compared with 2621 in the high-dose 
edoxaban group and 2673 in the low-dose edox-
aban group; P<0.001 for the comparisons of 
each dose of edoxaban with warfarin). Premature 
permanent discontinuation of the study drugs 
occurred in 2417 patients, 2415 patients, and 
2309 patients in the three groups, respectively 
(Table S1 in the Supplementary Appendix). In 
the warfarin group, the median time in the 
therapeutic range was 68.4% of the treatment 
period (interquartile range, 56.5 to 77.4), and the 
mean (±SD) time in the therapeutic range was 
64.9±18.7% of the treatment period; the INR was 
between 1.8 and 3.2 for 83.1% of the treatment 
period.
PRIMARY END POINT
During the treatment period, a stroke or system-
ic embolic event occurred in 232 patients in the 
warfarin group (representing a rate of 1.50% per 
year), as compared with 182 patients in the high-
dose edoxaban group (a rate of 1.18% per year; 
hazard ratio vs. warfarin, 0.79; 97.5% confidence 
interval [CI], 0.63 to 0.99; P<0.001 for noninferi-
ority, P = 0.02 for superiority) and 253 patients in 
the low-dose edoxaban group (a rate of 1.61% per 
year; hazard ratio vs. warfarin, 1.07; 97.5% CI, 
0.87 to 1.31; P = 0.005 for noninferiority, P = 0.44 
for superiority) (Table 2).
In the prespecified superiority analysis for 
efficacy that was performed in the intention-to-
treat population with data from the overall study 
period, the annualized rate of the primary end 
point was 1.80% in the warfarin group, as com-
pared with 1.57% in the high-dose edoxaban 
group (hazard ratio vs. warfarin, 0.87; 97.5% CI, 
0.73 to 1.04; P = 0.08) and 2.04% in the low-dose 
edoxaban group (hazard ratio vs. warfarin, 1.13; 
97.5% CI, 0.96 to 1.34; P = 0.10) (Table 2 and 
Fig. 1A). The annualized rate of hemorrhagic 
stroke was 0.47% with warfarin, as compared 
with 0.26% with high-dose edoxaban (hazard 
ratio, 0.54; 95% CI, 0.38 to 0.77; P<0.001) and 
0.16% with low-dose edoxaban (hazard ratio, 
0.33; 95% CI, 0.22 to 0.50; P<0.001). The rate of 
ischemic stroke was 1.25% with warfarin as 
compared with 1.25% with high-dose edoxaban 
(hazard ratio, 1.00; 95% CI, 0.83 to 1.19; 
P = 0.97) and 1.77% with low-dose edoxaban 
(hazard ratio, 1.41; 95% CI, 1.19 to 1.67; 
P<0.001).
At the end of the trial, seven primary-end-
point events occurred in each treatment group 
during the 30-day transition period from treat-
ment with the blinded study drug to receipt of an 
open-label anticoagulant agent. The rates of major 
bleeding and death were also similar among the 
treatment groups during this transition period.
BLEEDING
The annualized rate of major bleeding events was 
3.43% with warfarin, as compared with 2.75% 
with high-dose edoxaban (hazard ratio, 0.80; 95% 
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CI, 0.71 to 0.91; P<0.001) and 1.61% with low-
dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 
to 0.55; P<0.001) (Table 3 and Fig. 1B). The rates 
of life-threatening bleeding, intracranial bleed-
ing, and major bleeding plus clinically relevant 
nonmajor bleeding were 0.78%, 0.85%, and 
13.02%, respectively, with warfarin, as compared 
with 0.40%, 0.39%, and 11.10%, respectively, with 
high-dose edoxaban and 0.25%, 0.26%, and 
7.97%, respectively, with low-dose edoxaban 
(P<0.001 for the comparison of warfarin with 
each dose of edoxaban). The annualized rate of 
major gastrointestinal bleeding was higher with 
high-dose edoxaban than with warfarin (1.51% 
vs. 1.23%), but the rate was lowest with low-dose 
edoxaban (0.82%).
SECONDARY AND OTHER EFFICACY OUTCOMES
The rates of all three prespecified secondary com-
posite outcomes were significantly lower with 
high-dose edoxaban than with warfarin (Table 2); 
there were no significant differences between 
low-dose edoxaban and warfarin in the rates of 
those outcomes. Treatment with edoxaban was 
associated with lower annualized rates of death 
from cardiovascular causes than was warfarin: 
3.17% with warfarin, as compared with 2.74% 
with high-dose edoxaban (hazard ratio, 0.86; 
95% CI, 0.77 to 0.97; P = 0.01) and 2.71% with 
low-dose edoxaban (hazard ratio, 0.85; 95% CI, 
0.76 to 0.96; P = 0.008), with findings in a sim ilar 
direction for the rate of death from any cause.
The annualized rate of the primary net clinical 
outcome (death from any cause, stroke, systemic 
embolic event, or major bleeding) was signifi-
cantly lower with both edoxaban regimens than 
with warfarin: 8.11% with warfarin, as compared 
with 7.26% with high-dose edoxaban (hazard 
ratio, 0.89; 95% CI, 0.83 to 0.96; P = 0.003) and 
6.79% with low dose-edoxaban (hazard ratio, 
0.83; 95% CI, 0.77 to 0.90; P<0.001) (Table 3). 
Similarly, as compared with warfarin, both edox-
aban regimens were associated with significantly 
lower rates of the secondary net clinical outcome 
of death from any cause, disabling stroke, or life-
threatening bleeding, and the tertiary net clinical 
outcome of stroke, systemic embolic event, life-
threatening bleeding, or death from any cause.
SUBGROUPS
In subgroup analyses of the primary efficacy 
end point, there were significant interactions O
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(at P<0.05) between treatment and subgroups 
defined according to status with respect to pre-
vious receipt of a vitamin K antagonist (warfa-
rin vs. both edoxaban groups), concurrent aspirin 
use (warfarin vs. low-dose edoxaban group), and 
concurrent amiodarone use (warfarin vs. low-dose 
edoxaban group) (Fig. S3 in the Supple mentary 
Appendix). The reduction in major bleeding with 
edoxaban as compared with warfarin was signifi-
cantly greater among patients who received a dose 
reduction at randomization than among those 
who did not receive a dose reduction (Fig. S4 in 
the Supplementary Appendix).
OTHER SAFETY OUTCOMES
The rates of adverse events and serious adverse 
events were similar in the three groups (Table S1 
in the Supplementary Appendix). The proportions 
of patients with an elevated level of liver enzymes 
or with hepatocellular injury were also similar in 
the three groups.
COMPARISON OF EDOXABAN REGIMENS
In the intention-to-treat analysis, the rate of 
stroke or systemic embolic event was lower with 
high-dose edoxaban than with low-dose edoxa-
ban (P<0.001); this difference was driven by a 
relative reduction in the incidence of ischemic 
stroke of 29% with high-dose edoxaban (236 vs. 
333 events), which more than offset a higher inci-
dence of hemorrhagic stroke (49 events, vs. 30 
events with low-dose edoxaban), although the 
hemorrhagic strokes had more severe sequelae 
than the ische mic strokes. As compared with 
high-dose edoxaban, low-dose edoxaban was asso-
ciated with significantly lower rates of bleeding, 
including major bleeding, intracranial bleeding, 
and major or clinically relevant nonmajor bleed-
ing. There were no significant differences between 
the two edoxaban groups in the rates of death 
from cardiovascular causes and death from any 
cause.
DISCUSSION
In this trial, both edoxaban regimens were non-
inferior to well-managed warfarin (median time 
in the therapeutic range, 68.4% of the treatment 
period) for the prevention of stroke or systemic 
embolic event; the high-dose edoxaban regimen 
tended to be more effective than warfarin. The 
rate of ischemic stroke was similar with high-
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Figure 1. Kaplan–Meier Curves for the Primary Efficacy and Principal Safety 
End Points.
Panel A shows the cumulative event rates for stroke or systemic embolism 
in the intention-to-treat population (all patients who underwent random-
ization) during the overall study period (i.e., beginning from the time of 
randomization to the end of the double-blind treatment period); data from 
the overall study period, rather than the treatment period only, were used 
in the superiority analyses of efficacy. Panel B shows the principal safety 
outcome of major bleeding, defined according to the criteria of the Inter-
national Society on Thrombosis and Haemostasis,10 in the safety popula-
tion during the treatment period. The Kaplan–Meier curve was drawn with-
out interval censoring for treatment interruptions. The inset in each panel 
shows the same data on an enlarged segment of the y axis.
The New England Journal of Medicine 
Downloaded from nejm.org at Radboud University Nijmegen on March 19, 2019. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
Edoxaban vs. Warfarin in Atrial Fibrillation
n engl j med 369;22 nejm.org november 28, 2013 2101
Ta
bl
e 
3.
 S
af
et
y 
an
d 
N
et
 C
lin
ic
al
 E
nd
 P
oi
nt
s.
*
O
ut
co
m
e
W
ar
fa
ri
n
(N
 =
 7
01
2)
H
ig
h-
D
os
e 
Ed
ox
ab
an
 
(N
 =
 7
01
2)
H
ig
h-
D
os
e 
Ed
ox
ab
an
 
vs
. W
ar
fa
ri
n
Lo
w
-D
os
e 
Ed
ox
ab
an
(N
 =
 7
00
2)
Lo
w
-D
os
e 
Ed
ox
ab
an
 
vs
. W
ar
fa
ri
n
H
az
ar
d 
R
at
io
(9
5%
 C
I)
P 
V
al
ue
H
az
ar
d 
R
at
io
(9
5%
 C
I)
P 
V
al
ue
no
. o
f  
pa
tie
nt
s 
 
w
ith
 e
ve
nt
%
 o
f 
pa
tie
nt
s/
yr
no
. o
f 
pa
tie
nt
s 
w
ith
 e
ve
nt
%
 o
f  
pa
tie
nt
s/
yr
no
. o
f  
pa
tie
nt
s 
w
ith
 e
ve
nt
%
 o
f  
pa
tie
nt
s/
yr
M
aj
or
 b
le
ed
in
g
52
4
3.
43
41
8
2.
75
0.
80
 (
0.
71
–0
.9
1)
<0
.0
01
25
4
1.
61
0.
47
 (
0.
41
–0
.5
5)
<0
.0
01
Fa
ta
l
59
0.
38
32
0.
21
0.
55
 (
0.
36
–0
.8
4)
0.
00
6
21
0.
13
0.
35
 (
0.
21
–0
.5
7)
<0
.0
01
B
le
ed
in
g 
in
to
 a
 c
ri
tic
al
 o
rg
an
 o
r 
ar
ea
21
1
1.
36
10
8
0.
70
0.
51
 (
0.
41
–0
.6
5)
<0
.0
01
69
0.
44
0.
32
 (
0.
24
–0
.4
2)
<0
.0
01
O
ve
rt
 b
le
ed
in
g 
w
ith
 b
lo
od
 lo
ss
 o
f ≥
2 
g/
dl
32
7
2.
13
31
7
2.
08
0.
98
 (
0.
84
–1
.1
4)
0.
78
18
7
1.
19
0.
56
 (
0.
47
–0
.6
7)
<0
.0
01
A
ny
 in
tr
ac
ra
ni
al
 b
le
ed
in
g
13
2
0.
85
61
0.
39
0.
47
 (
0.
34
–0
.6
3)
<0
.0
01
41
0.
26
0.
30
 (
0.
21
–0
.4
3)
<0
.0
01
Fa
ta
l i
nt
ra
cr
an
ia
l b
le
ed
in
g
42
0.
27
24
0.
15
0.
58
 (
0.
35
–0
.9
5)
0.
03
12
0.
08
0.
28
 (
0.
15
–0
.5
3)
<0
.0
01
G
as
tr
oi
nt
es
tin
al
 b
le
ed
in
g
19
0
1.
23
23
2
1.
51
1.
23
 (
1.
02
–1
.5
0)
0.
03
12
9
0.
82
0.
67
 (
0.
53
–0
.8
3)
<0
.0
01
U
pp
er
 g
as
tr
oi
nt
es
tin
al
 tr
ac
t
11
1
0.
71
14
0
0.
91
1.
27
 (
0.
99
–1
.6
3)
0.
06
88
0.
56
0.
78
 (
0.
59
–1
.0
3)
0.
08
Lo
w
er
 g
as
tr
oi
nt
es
tin
al
 tr
ac
t
81
0.
52
96
0.
62
1.
20
 (
0.
89
–1
.6
1)
0.
23
44
0.
28
0.
54
 (
0.
37
–0
.7
7)
<0
.0
01
B
le
ed
in
g 
in
 o
th
er
 lo
ca
tio
n
21
1
1.
37
13
1
0.
85
0.
62
 (
0.
50
–0
.7
8)
<0
.0
01
87
0.
55
0.
40
 (
0.
31
–0
.5
2)
<0
.0
01
B
le
ed
in
g 
du
ri
ng
 tr
an
si
tio
n 
to
 o
pe
n-
la
be
l 
or
al
 a
nt
ic
oa
gu
la
tio
n 
th
er
ap
y
D
ay
 1
–1
4
6
—
4
—
—
—
5
—
—
—
D
ay
 1
5–
30
5
—
6
—
—
—
13
—
—
—
Li
fe
-t
hr
ea
te
ni
ng
 b
le
ed
in
g
12
2
0.
78
62
0.
40
0.
51
 (
0.
38
–0
.7
0)
<0
.0
01
40
0.
25
0.
32
 (
0.
23
–0
.4
6)
<0
.0
01
C
lin
ic
al
ly
 r
el
ev
an
t n
on
m
aj
or
 b
le
ed
in
g
13
96
10
.1
5
12
14
8.
67
0.
86
 (
0.
79
–0
.9
3)
<0
.0
01
96
9
6.
60
0.
66
 (
0.
60
–0
.7
1)
<0
.0
01
M
in
or
 b
le
ed
in
g
71
4
4.
89
60
4
4.
12
0.
84
 (
0.
76
–0
.9
4)
0.
00
2
53
3
3.
52
0.
72
 (
0.
65
–0
.8
1)
<0
.0
01
M
aj
or
 o
r 
cl
in
ic
al
ly
 r
el
ev
an
t n
on
m
aj
or
 b
le
ed
in
g
17
61
13
.0
2
15
28
11
.1
0
0.
86
 (
0.
80
–0
.9
2)
<0
.0
01
11
61
7.
97
0.
62
 (
0.
57
–0
.6
7)
<0
.0
01
A
ny
 o
ve
rt
 b
le
ed
in
g
21
14
16
.4
0
18
65
14
.1
5
0.
87
 (
0.
82
–0
.9
2)
<0
.0
01
14
99
10
.6
8
0.
66
 (
0.
62
–0
.7
1)
<0
.0
01
N
et
 c
lin
ic
al
 o
ut
co
m
e†
Pr
im
ar
y
14
62
8.
11
13
23
7.
26
0.
89
 (
0.
83
–0
.9
6)
0.
00
3
12
48
6.
79
0.
83
 (
0.
77
–0
.9
0)
<0
.0
01
Se
co
nd
ar
y
98
7
5.
23
88
3
4.
64
0.
88
 (
0.
81
–0
.9
7)
0.
00
8
83
7
4.
38
0.
83
 (
0.
76
–0
.9
1)
<0
.0
01
Te
rt
ia
ry
11
23
6.
02
99
9
5.
30
0.
88
 (
0.
81
–0
.9
6)
0.
00
3
10
10
5.
37
0.
89
 (
0.
82
–0
.9
7)
0.
00
7
* 
D
at
a 
ar
e 
fr
om
 t
he
 s
af
et
y 
co
ho
rt
 d
ur
in
g 
th
e 
tr
ea
tm
en
t 
pe
ri
od
 (
w
hi
ch
 b
eg
an
 w
he
n 
th
e 
fir
st
 d
os
e 
of
 s
tu
dy
 d
ru
g 
w
as
 a
dm
in
is
te
re
d)
, w
ith
 in
te
rv
al
 c
en
so
ri
ng
 o
f e
ve
nt
s 
du
ri
ng
 s
tu
dy
-d
ru
g 
in
te
rr
up
tio
ns
 t
ha
t 
la
st
ed
 m
or
e 
th
an
 3
 d
ay
s,
 e
xc
ep
t 
fo
r 
ne
t 
cl
in
ic
al
 o
ut
co
m
es
, w
hi
ch
 a
re
 p
re
se
nt
ed
 fo
r 
th
e 
ov
er
al
l t
re
at
m
en
t 
pe
ri
od
 (
w
hi
ch
 b
eg
an
 a
t 
th
e 
tim
e 
of
 r
an
do
m
iz
at
io
n)
.
†
 T
he
 p
ri
m
ar
y 
ne
t 
cl
in
ic
al
 o
ut
co
m
e 
w
as
 a
 c
om
po
si
te
 o
f s
tr
ok
e,
 s
ys
te
m
ic
 e
m
bo
lic
 e
ve
nt
, m
aj
or
 b
le
ed
in
g,
 o
r 
de
at
h 
fr
om
 a
ny
 c
au
se
. T
he
 s
ec
on
da
ry
 n
et
 c
lin
ic
al
 o
ut
co
m
e 
w
as
 a
 c
om
po
si
te
 o
f 
di
sa
bl
in
g 
st
ro
ke
, l
ife
-t
hr
ea
te
ni
ng
 b
le
ed
in
g,
 o
r 
de
at
h 
fr
om
 a
ny
 c
au
se
. T
he
 t
er
tia
ry
 n
et
 c
lin
ic
al
 o
ut
co
m
e 
w
as
 a
n 
ex
pl
or
at
or
y 
co
m
po
si
te
 o
f s
tr
ok
e,
 s
ys
te
m
ic
 e
m
bo
lic
 e
ve
nt
, l
ife
-t
hr
ea
te
ni
ng
 
bl
ee
di
ng
, o
r 
de
at
h 
fr
om
 a
ny
 c
au
se
.
The New England Journal of Medicine 
Downloaded from nejm.org at Radboud University Nijmegen on March 19, 2019. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 369;22 nejm.org november 28, 20132102
dose edoxaban and warfarin but was higher with 
the low-dose edoxaban regimen. The incidence 
of hemorrhagic stroke and the rate of death from 
cardiovascular causes were significantly lower 
with both edoxaban regimens than with warfarin.
As compared with warfarin, edoxaban was 
associated with consistently lower, dose-related 
rates of all types of bleeding, including major 
bleeding, intracranial bleeding, and life-threaten-
ing bleeding. The single exception was gastro-
intestinal bleeding, which occurred more frequent-
ly with high-dose edoxaban but less frequently 
with low-dose edoxaban than it did with warfa-
rin. The rates of net clinical outcomes, which were 
composites of cardiovascular events, death from 
any cause, or bleeding, were significantly lower 
with both edoxaban regimens than with warfarin. 
The very low rate of missing data (0.5%) under-
scores the robustness of these observations.13,14
The primary efficacy and safety findings were 
consistent across major subgroups, including 
those defined according to demographic charac-
teristics of the patients, risk of stroke (as defined 
by the CHADS2 score), and geographic region, 
with three notable exceptions. First, patients who 
had not previously received a vitamin K antago-
nist had significantly fewer stroke or systemic 
embolic events with high-dose edoxaban than 
with warfarin, whereas the rates were similar 
among patients who had previously received a 
vitamin K antagonist. Second, the concomitant 
use of amiodarone and low-dose edoxaban, as 
well as the concomitant use of aspirin and low-
dose edoxaban, appeared to increase the treat-
ment effect of low-dose edoxaban — a finding 
that was possibly related to a modest increase in 
edoxaban levels with amiodarone15 and enhanced 
stroke prevention with aspirin.11 Third, a reduc-
tion in the edoxaban dose in patients with mod-
erate renal impairment, a body weight of 60 kg 
or less, or the concomitant use of P-glycoprotein 
inhibitors was associated with a decreased risk 
of bleeding with both regimens. Subgroup anal-
yses exploring relationships among safety, effi-
cacy, and dose reduction (as compared with no 
dose reduction) showed an even greater reduc-
tion in bleeding with edoxaban as compared 
with warfarin among patients who underwent 
dose reduction, without an apparent loss in ef-
ficacy (Fig. S3 and S4 in the Supplementary 
Appendix). In addition, dose modifications were 
permitted after randomization, since factors 
that affect drug clearance may vary over time.
Edoxaban appeared to be safe, had no unex-
pected side effects, had fewer side effects than 
warfarin (as managed with a median time in the 
therapeutic range of 68.4% of the treatment pe-
riod), and had a favorable net clinical outcome. 
Although no specific antidote for edoxaban is 
currently available, hemostatic agents reverse its 
anticoagulant effect.16 The availability of a reli-
able factor Xa assay17 and specific reversal strat-
egies18 in urgent clinical situations could poten-
tially improve the safety profile of edoxaban, but 
no particular strategy is well accepted in practice 
at this time. The rate of myocardial infarction was 
not altered with edoxaban, and there was no 
increase in the risk of stroke or bleeding when 
patients in the edoxaban groups made the tran-
sition to open-label anticoagulant therapy at the 
end of the study.
In previous studies involving patients with 
atrial fibrillation, dabigatran, rivaroxaban, and 
apixaban were at least as efficacious as warfarin 
and were associated with lower rates of intracra-
nial bleeding.19-21 Similar to edoxaban, these 
drugs can be given in fixed doses without rou-
tine laboratory monitoring and have fewer drug–
drug and food–drug interactions than vitamin K 
antagonists. Although there may be subtle differ-
ences among the new anticoagulant agents with 
respect to the prevention of ischemic stroke, 
myocardial infarction, bleeding, or death,22 di-
rect comparative studies are needed to determine 
whether these are real differences in clinical ef-
ficacy and safety or whether they reflect differ-
ences in the pharmacologic properties, the doses 
used, the patient populations, the quality of 
warfarin management, or other aspects of the 
trial designs.23
Strengths of the ENGAGE AF-TIMI 48 trial 
include the large sample size, long follow-up, 
minimal amount of missing data, greater-than-
average time in the therapeutic range in the 
warfarin group, and the inclusion of multiple 
once-daily doses24,25 of a new anticoagulant agent 
ranging from 15 to 60 mg with dynamic dose 
modification. In addition, the implementation of 
a comprehensive transition plan to open-label 
anticoagulation therapy resulted in a low and 
evenly distributed number of events after the 
discontinuation of study therapy. This finding 
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makes it unlikely that there is a rebound activa-
tion of coagulation after the discontinuation of 
edoxaban.
In conclusion, both once-daily regimens of 
edoxaban were noninferior to warfarin for the 
prevention of stroke or systemic embolism and 
were associated with significantly lower rates of 
bleeding and death from cardiovascular causes.
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